Daily Roundup

Wednesday, 18th November 2026 · updated 21:00

Tasmea on a Roll with Second Guidance Upgrade

Tasmea Limited is riding high after upgrading its FY27 earnings guidance for the second time, buoyed by a record first quarter and booming demand for specialist services. The company now expects underlying EBITA of A$210-215 million and underlying NPATA of A$133-136 million, a significant jump from previous forecasts. The standout performer has been organic growth, which surged above 15% in Q1, while recent acquisitions of Maxim Group and JPS Group are already punching above their weight. With a strong balance sheet and A$250 million in undrawn debt capacity, Tasmea is well-positioned to keep the momentum rolling.

EML Payments Holds Steady Despite Revenue Dip

EML Payments Ltd reported Q1 trading in line with expectations, though the quarter wasn't without its bumps. Revenue slipped 3% to A$46.2 million, and gross profit declined 4% to A$33.7 million. However, the company managed to keep net overheads down 6% to A$26.6 million, which helped underlying EBITDA climb 6% to A$7.1 million. More importantly, EML achieved a perfect 100% renewal rate on its top 30 contracts, a crucial metric in the payments space. The company reaffirmed its FY27 underlying EBITDA guidance of A$50-54 million and is on track with Project Arlo while building its commercial pipeline toward A$150 million by June 2027.

Microba-GSS Merger Collapses

The proposed merger between Microba Life Sciences and Genetic Signatures has fallen apart, with both companies announcing the deal won't proceed. Microba lacked the financial firepower to complete the transaction, unable to secure the additional capital needed after revised terms made its institutional placement untenable. Genetic Signatures, for its part, decided against providing unsecured debt funding to bridge the gap, citing the risks involved. Microba remains in voluntary suspension while it explores alternative funding options.

New Hope Strikes Gold with Hybrid Securities

New Hope Corporation successfully completed a bookbuild for perpetual step-up hybrid securities that exceeded expectations. Investor demand was so strong that the company nearly doubled the offer size to A$500 million from the initially planned A$250 million. The margin was set at a competitive 4.00% per annum. A replacement prospectus will hit the ASX on 24 November, with the offer opening that same day and closing on 9 December.

Cettire Hits Its Stride with Profitability Gains

Luxury e-commerce platform Cettire is firing on all cylinders, reporting strong growth and improved profitability for the four months ended 31 October. Gross revenue jumped 18% to A$331 million, while sales revenue climbed 15% to A$246.2 million. The delivered margin improved to 17.1%, and adjusted EBITDA nearly doubled to A$6.9 million. Active customers grew 3% to around 650,000, and the company sits in a healthy position with A$27 million in cash and zero debt. Management expects profitability to continue into Q2 as the company pushes forward with geographic revenue diversification.

References